For decades, HER2 status in breast cancer has served as one of the most critical determinants of treatment selection. Patients were traditionally categorized as either HER2-positive or HER2-negative, with targeted therapies reserved exclusively for those with HER2 overexpression or gene amplification. This binary classification shaped clinical decision-making, clinical trial design, and therapeutic expectations.
The DESTINY-Breast clinical trial program has fundamentally changed this paradigm.
With the development of trastuzumab deruxtecan (T-DXd), a next-generation antibody–drug conjugate (ADC), the field has moved from a binary understanding of HER2 biology to a spectrum-based model. This shift has introduced the concept of HER2-low breast cancer, dramatically expanding the population eligible for targeted therapy and redefining treatment algorithms across multiple disease settings (Modi et al., 2022).
The DESTINY-Breast trials are not simply incremental studies evaluating a new drug. They represent a coordinated, strategic clinical development program that spans heavily pretreated metastatic disease, earlier lines of therapy, and now early-stage settings. Together, they have reshaped the understanding of HER2 biology, challenged long-standing treatment hierarchies, and accelerated the integration of precision oncology into routine clinical practice.
Understanding Trastuzumab Deruxtecan: Why This Drug Changed Everything
To understand the impact of the DESTINY program, it is essential to examine the mechanism of trastuzumab deruxtecan.
T-DXd is composed of three critical components: a monoclonal antibody targeting HER2, a cleavable linker, and a potent topoisomerase I inhibitor payload. While this structure may appear similar to earlier ADCs such as trastuzumab emtansine (T-DM1), several key differences account for its superior clinical activity.
First, T-DXd has a high drug-to-antibody ratio, approximately eight payload molecules per antibody, allowing for enhanced cytotoxic delivery. Second, the linker is designed to remain stable in circulation but release the payload efficiently once internalized into tumor cells. Third, and most importantly, the payload is membrane-permeable, enabling a “bystander effect,” whereby neighboring tumor cells, regardless of HER2 expression, can also be targeted (Modi et al., 2020).
This bystander effect is particularly relevant in breast cancer, where intratumoral heterogeneity is common. Tumors often contain a mix of HER2-expressing and non-expressing cells, and traditional HER2-targeted therapies may fail to eradicate all malignant clones. T-DXd overcomes this limitation, contributing to its high response rates across diverse patient populations.
Clinically, this translates into deeper and more durable responses, activity in HER2-low disease, and potential efficacy in tumors previously considered resistant to HER2-targeted approaches.
DESTINY-Breast01: Establishing Proof of Concept
DESTINY-Breast01 was the first pivotal study to demonstrate the clinical potential of T-DXd.
This phase II, single-arm trial enrolled patients with heavily pretreated HER2-positive metastatic breast cancer, most of whom had received multiple prior lines of therapy, including trastuzumab, pertuzumab, and T-DM1. The population represented a group with limited therapeutic options and historically poor outcomes.
Despite this, the study reported an objective response rate of 60.9%, with a median progression-free survival of 16.4 months (Modi et al., 2020). These results were unprecedented in such a refractory setting and immediately positioned T-DXd as a highly active therapy.
However, DESTINY-Breast01 also identified an important safety concern: interstitial lung disease (ILD). Approximately 13.6% of patients developed ILD, including some fatal cases. This finding highlighted the need for careful monitoring and risk mitigation strategies in subsequent trials.
Overall, DESTINY-Breast01 established both the efficacy and the challenges associated with T-DXd, setting the stage for randomized studies.
DESTINY-Breast03: A New Standard of Care
DESTINY-Breast03 marked a turning point in breast cancer treatment. This phase III trial compared T-DXd directly with T-DM1 in patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane. The results were dramatic.
Median progression-free survival was not reached in the T-DXd arm compared with 6.8 months in the T-DM1 arm, corresponding to a hazard ratio of 0.28 (Cortés et al., 2022). Updated analyses confirmed a significant overall survival benefit.
The magnitude of benefit observed in this trial was unprecedented and led to the rapid adoption of T-DXd as the preferred second-line therapy in HER2-positive metastatic breast cancer.
Importantly, while ILD remained a concern, improved monitoring and earlier intervention reduced the incidence of severe cases. This demonstrated that with appropriate management, the benefits of T-DXd could outweigh its risks.
DESTINY-Breast02: Confirming Efficacy After T-DM1
DESTINY-Breast02 addressed an important clinical question: does T-DXd retain efficacy in patients previously treated with T-DM1?
In this randomized phase III trial, T-DXd was compared with physician’s choice chemotherapy in patients with HER2-positive metastatic breast cancer who had progressed after T-DM1. The results confirmed a clear advantage for T-DXd.
Median progression-free survival was 17.8 months with T-DXd versus 6.9 months with chemotherapy, and overall survival was also significantly improved (André et al., 2023).
This trial reinforced the role of T-DXd across multiple lines of therapy and demonstrated its ability to overcome resistance to prior HER2-directed treatments.
DESTINY-Breast04: Redefining HER2 Biology
DESTINY-Breast04 is widely considered one of the most practice-changing trials in modern oncology.
This phase III study enrolled patients with HER2-low metastatic breast cancer, defined as tumors with low HER2 expression (IHC 1+ or 2+/ISH-negative). Historically, these patients were classified as HER2-negative and treated with chemotherapy.
The results were transformative.
In hormone receptor–positive patients, median progression-free survival was 10.1 months with T-DXd versus 5.4 months with chemotherapy. Overall survival improved from 17.5 months to 23.9 months (Modi et al., 2022).
The benefit extended across the overall population, including hormone receptor, negative patients.
This trial did more than introduce a new therapy, it redefined a disease category. HER2-low is now recognized as a clinically actionable subtype, fundamentally altering diagnostic and therapeutic approaches.
DESTINY-Breast05: Moving Into Early-Stage Disease
DESTINY-Breast05 represents a critical step in expanding T-DXd into earlier disease settings.
This ongoing phase III trial is evaluating T-DXd versus T-DM1 in patients with high-risk HER2-positive early breast cancer who have residual disease after neoadjuvant therapy. This population is at significant risk of recurrence, and improving outcomes in this setting remains a major clinical priority.
The rationale is straightforward: if T-DXd is superior to T-DM1 in metastatic disease, it may also provide greater benefit in early-stage disease.
The results of this trial have the potential to shift T-DXd into curative-intent treatment strategies.
Read About DESTINY-Breast 05 Trial on OncoDaily
DESTINY-Breast06: Expanding HER2-Low Into Earlier Lines
DESTINY-Breast06 builds on the success of DESTINY-Breast04 by evaluating T-DXd in earlier lines of metastatic disease.
This trial focuses on patients with hormone receptor–positive, HER2-low breast cancer who have progressed on endocrine therapy but have not yet received extensive chemotherapy. The goal is to introduce T-DXd earlier, reducing reliance on cytotoxic treatments and improving patient quality of life.
This approach reflects a broader trend in oncology: moving effective targeted therapies earlier in the disease course.
DESTINY-Breast07 and 08: Exploring Combination Strategies
As the DESTINY program evolves, attention has shifted toward combination therapies.
DESTINY-Breast07 is evaluating T-DXd in combination with immune checkpoint inhibitors and other targeted agents. The rationale is that combining ADCs with immunotherapy may enhance antitumor activity and overcome resistance mechanisms.
DESTINY-Breast08 is exploring similar strategies in hormone receptor–positive disease, integrating T-DXd with endocrine therapies and other targeted agents.
These trials represent the next phase of development, focusing on optimizing efficacy through rational combinations.
DESTINY-Breast09: The First-Line Frontier
DESTINY-Breast09 is one of the most anticipated trials in the program.
This phase III study is evaluating T-DXd-based regimens in the first-line setting for HER2-positive metastatic breast cancer. If successful, it could redefine first-line therapy and position T-DXd as the backbone of treatment from the outset.
The results of this trial will be critical in determining how early T-DXd should be introduced in the treatment sequence.
Read About DESTINY-Breast 09 Trial on OncoDaily
DESTINY-Breast11: Bringing T-DXd Into the Neoadjuvant Setting
DESTINY-Breast11 extends the scope of the DESTINY program into early-stage, high-risk HER2-positive breast cancer, evaluating trastuzumab deruxtecan (T-DXd) in the neoadjuvant setting. This marks an important transition from metastatic disease toward curative-intent treatment strategies.
The trial investigates whether T-DXd-based regimens can improve pathologic complete response (pCR) rates compared with standard neoadjuvant approaches, which typically combine chemotherapy with dual HER2 blockade. Achieving pCR has consistently been associated with improved long-term outcomes, including event-free and overall survival, making it a critical endpoint in early HER2-positive disease.
The rationale for DESTINY-Breast11 is grounded in the substantial efficacy observed with T-DXd in advanced settings, particularly its high response rates and durable disease control (Cortés et al., 2022). Translating this activity into earlier disease stages raises the possibility of deeper tumor eradication before surgery and improved long-term outcomes.
If positive, DESTINY-Breast11 could significantly influence clinical practice by redefining neoadjuvant standards, potentially reducing reliance on conventional chemotherapy, and establishing antibody–drug conjugate, based strategies as part of frontline treatment. More broadly, it reflects the ongoing evolution of the DESTINY program, moving highly effective targeted therapies earlier in the disease course, where the potential for cure is greatest.
Read About DESTINY-Breast 11 Trial on OncoDaily
Safety Considerations: Managing Interstitial Lung Disease
Despite its remarkable efficacy, T-DXd is associated with a unique toxicity profile, most notably interstitial lung disease.
Across trials, ILD has been reported in approximately 10–15% of patients, with most cases being low grade but some resulting in severe or fatal outcomes (Cortés et al., 2022).
Early detection is essential. Clinicians must maintain a high index of suspicion, particularly in patients presenting with respiratory symptoms. Prompt initiation of corticosteroids and treatment interruption can mitigate progression.
The management of ILD has improved significantly over time, reflecting increased awareness and experience among clinicians.
Broader Impact: Redefining Breast Cancer Treatment
The DESTINY-Breast program has had far-reaching implications beyond individual trial results.
First, it has redefined HER2 biology, introducing HER2-low as a clinically meaningful category. Second, it has demonstrated the power of next-generation ADCs to overcome resistance and improve outcomes. Third, it has accelerated the integration of precision oncology into routine practice.
Perhaps most importantly, it has changed how clinical trials are designed. The simultaneous exploration of multiple disease settings has allowed for rapid translation of findings into clinical practice.
Future Directions
The DESTINY-Breast program continues to evolve.
Ongoing studies are exploring T-DXd in earlier disease settings, combination regimens, and new patient populations. Additionally, efforts are underway to better understand resistance mechanisms and identify biomarkers that can predict response.
As these studies mature, they will further refine the role of T-DXd and expand its applications.
Conclusion
The DESTINY-Breast clinical trial program represents a landmark achievement in oncology.
By challenging traditional classifications, leveraging innovative drug design, and rapidly expanding across clinical settings, it has transformed the treatment landscape for breast cancer.
What began as a promising therapy for heavily pretreated patients has evolved into a cornerstone of modern breast cancer treatment, with the potential to impact outcomes across the entire disease spectrum.